Loading...
XTAI
4746
Market cap279mUSD
Jun 13, Last price  
68.50TWD
1D
-1.44%
1Q
-4.33%
Jan 2017
-31.16%
IPO
-26.31%
Name

Formosa Laboratories Inc

Chart & Performance

D1W1MN
No data to show
P/E
52.38
P/S
1.74
EPS
1.31
Div Yield, %
2.92%
Shrs. gr., 5y
3.30%
Rev. gr., 5y
11.38%
Revenues
4.73b
+8.50%
02,505,914,0002,625,647,0002,524,282,0002,473,633,0002,496,224,0002,596,722,0003,189,380,0002,539,353,0002,687,731,0002,759,591,0003,075,457,0003,142,406,0003,765,504,0004,360,448,0004,731,046,000
Net income
157m
+24.58%
0246,621,000231,067,0005,003,000-69,401,000262,495,000282,392,000483,441,000238,645,000176,821,000-41,062,000400,034,0001,249,096,000216,810,000126,243,000157,268,000
CFO
726m
-12.13%
099,671,000-11,231,000171,135,00032,253,000280,408,000255,149,0001,110,075,000395,419,000-80,894,000289,924,000475,004,000311,157,000643,086,000826,600,000726,334,000
Dividend
Aug 13, 20242 TWD/sh
Earnings
Jun 25, 2025

Profile

Formosa Laboratories, Inc. produces and sells active pharmaceutical ingredients (APIs) worldwide. The company offers APIs in the areas of anticancer, anti-inflammatory and analgesic agents, MRI enhancing agents, cholesterol and phosphate binders, CNS agents, immunomodulators, respiratory agents, steroids, vitamin D derivatives, and antibiotics. It also provides contract development and manufacturing services; solutions for manufacturing antibody-drug conjugates; and injectable manufacturing services. The company was founded in 1995 and is based in Taoyuan City, Taiwan.
URL
https://www.formosalab.com/
IPO date
Nov 27, 2009
Employees
Domiciled in
TW
Incorporated in
TW

Valuation

Title
TWD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
4,731,046
8.50%
4,360,448
15.80%
3,765,504
19.83%
Cost of revenue
3,981,009
3,711,936
3,573,667
Unusual Expense (Income)
NOPBT
750,037
648,512
191,837
NOPBT Margin
15.85%
14.87%
5.09%
Operating Taxes
134,075
194,650
116,371
Tax Rate
17.88%
30.01%
60.66%
NOPAT
615,962
453,862
75,466
Net income
157,268
24.58%
126,243
-41.77%
216,810
-82.64%
Dividends
(240,512)
(120,256)
(240,512)
Dividend yield
2.97%
0.98%
2.71%
Proceeds from repurchase of equity
BB yield
Debt
Debt current
1,148,109
2,007,118
2,141,702
Long-term debt
2,860,640
2,100,037
1,702,721
Deferred revenue
28,941
18,227
16,989
Other long-term liabilities
90,745
84,781
111,976
Net debt
1,162,787
(353,176)
310,506
Cash flow
Cash from operating activities
726,334
826,600
643,086
CAPEX
(585,953)
(540,506)
(439,982)
Cash from investing activities
(1,025,673)
(1,257,426)
(540,721)
Cash from financing activities
132,091
117,457
447,945
FCF
50,448
227,742
168,769
Balance
Cash
2,703,390
2,510,488
1,630,531
Long term investments
142,572
1,949,843
1,903,386
Excess cash
2,609,410
4,242,309
3,345,642
Stockholders' equity
4,393,414
4,111,022
4,281,785
Invested Capital
10,057,317
8,266,593
8,239,116
ROIC
6.72%
5.50%
0.91%
ROCE
5.91%
5.23%
1.65%
EV
Common stock shares outstanding
117,742
120,491
120,884
Price
68.80
-32.55%
102.00
38.78%
73.50
21.49%
Market cap
8,100,657
-34.09%
12,290,082
38.32%
8,884,974
20.87%
EV
10,226,141
12,576,155
9,471,109
EBITDA
1,256,969
1,136,841
662,752
EV/EBITDA
8.14
11.06
14.29
Interest
39,614
34,735
19,319
Interest/NOPBT
5.28%
5.36%
10.07%